249 related articles for article (PubMed ID: 9391693)
1. Muromonab-CD3 and antithymocyte globulin in renal transplantation.
Burk ML; Matuszewski KA
Ann Pharmacother; 1997 Nov; 31(11):1370-7. PubMed ID: 9391693
[TBL] [Abstract][Full Text] [Related]
2. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
3. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207
[TBL] [Abstract][Full Text] [Related]
4. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients.
Brennan DC; Schnitzler MA; Baty JD; Ceriotti CS; Lowell JA; Shenoy S; Howard TK; Woodward RS
Pharmacoeconomics; 1997 Mar; 11(3):237-45. PubMed ID: 10165313
[TBL] [Abstract][Full Text] [Related]
5. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.
Wilde MI; Goa KL
Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551
[TBL] [Abstract][Full Text] [Related]
6. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
7. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
[TBL] [Abstract][Full Text] [Related]
8. Refractory acute renal allograft rejection successfully treated with photopheresis.
Genberg H; Kumlien G; Shanwell A; Tydén G
Transplant Proc; 2005 Oct; 37(8):3288-9. PubMed ID: 16298575
[TBL] [Abstract][Full Text] [Related]
9. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
Schulz T; Papapostolou G; Schenker P; Kapischke M
Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies in renal transplantation: a review.
Parlevliet KJ; Schellekens PT
Transpl Int; 1992 Sep; 5(4):234-46. PubMed ID: 1418316
[TBL] [Abstract][Full Text] [Related]
11. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster A; Pankhurst T; Rinaldi F; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2006 Apr; (2):CD004756. PubMed ID: 16625610
[TBL] [Abstract][Full Text] [Related]
12. Two approaches to comparing hospital charges between cadaveric renal transplant patients who received orthoclone OKT 3 sterile solution or Atgam sterile solution for induction therapy.
Schommer JC; Pleil AM; Pathak DS
Clin Ther; 1995; 17(4):749-69; discussion 748. PubMed ID: 8565038
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
[TBL] [Abstract][Full Text] [Related]
14. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review.
Nashan B
BioDrugs; 2005; 19(1):39-46. PubMed ID: 15691216
[TBL] [Abstract][Full Text] [Related]
15. A Cost-effectiveness Analysis of Rabbit Antithymocyte Globulin Versus Antithymocyte Globulin-fresenius as Induction Therapy for Patients With Kidney Transplantation From Donation After Cardiac Death in China.
Xuan D; Chen G; Wang C; Yao X; Yin H; Zhang L; Xuan J; Chen L
Clin Ther; 2018 Oct; 40(10):1741-1751. PubMed ID: 30243768
[TBL] [Abstract][Full Text] [Related]
16. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy.
Norman DJ; Barry JM; Bennett WM; Leone M; Henell K; Funnell B; Hubert B
Am J Kidney Dis; 1988 Feb; 11(2):90-3. PubMed ID: 3124611
[TBL] [Abstract][Full Text] [Related]
17. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
[TBL] [Abstract][Full Text] [Related]
18. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
Hariharan S; Alexander JW; Schroeder TJ; First MR
Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
[TBL] [Abstract][Full Text] [Related]
19. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
Cantarovich M; Latter DA; Loertscher R
Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
[TBL] [Abstract][Full Text] [Related]
20. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function.
Lange H; Müller TF; Ebel H; Kuhlmann U; Grebe SO; Heymanns J; Feiber H; Riedmiller H
Transpl Int; 1999; 12(1):2-9. PubMed ID: 10080400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
